Abstract
Introduction and hypothesis
This study was designed to evaluate the effects of CP55,940 on normal bladder function in vivo and examine whether it suppresses urinary frequency induced by nociceptive stimuli in the bladder. Cannabinoid receptor (CBR) activity may be involved in the regulation of bladder function. However, the role of CBR subtypes in micturition has yet to be established. CP55,940 is a synthetic analogue of tetrahydrocannabidiol, which is a psychoactive ingredient of the Cannabis plant.
Methods
Cystometry under urethane anaesthesia was performed to evaluate the effect of intravesical delivery of CP55,940 with or without administration of CB1 antagonist AM251 or CB2 antagonist AM630 on bladder function in female rats. The effects of CP55,940 were also examined in rats with urinary irritation induced by intravesical infusion of acetic acid.
Results
Infusion of CP55,940 significantly (p < 0.05) increased micturition interval (MI) and bladder capacity (BC) by 52 % and decreased maximal voiding pressure (MP) by 25 %. Pretreatment with AM251 or AM630 before CP55,940 administration prevented CP55,940-induced increases in MI, BC and reduced MP. Acetic acid induced urinary frequency as evidenced by a reduction in MI and was suppressed by CP55,940.
Conclusions
CP55,940 decreases bladder activity and urinary frequency induced by nociceptive stimuli, probably by suppression of bladder afferent activity. Effects of CP55,940 were abolished by both CBR antagonists. This data implicates a role for the endocannabinoid system in bladder mechanoafferent function in rats. In addition, our results show that CP55,940 reverses urinary frequency exemplified in an overactive bladder model, suggesting it could be an effective treatment for patients with lower urinary tract symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J (2006) The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 17(6):636–41
Pertwee RG, Howlett AC, Abood ME et al (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62(4):588–631
Bakali E, Elliott RA, Taylor AH, Willets J, Konje JC, Tincello DG (2013) Distribution and function of the endocannabinoid system in the rat and human bladder. Int Urogynecol J Pelvic Floor Dysfunct 24(5):855–63
Mukerji G, Yiangou Y, Agarwal SK, Anand P (2010) Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology 75(6):1514.e15-20
Hiragata S, Ogawa T, Hayashi Y et al (2007) Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 70(1):202–8
Dmitrieva N, Berkley KJ (2002) Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci 22(16):7147–53
Kakizaki H, de Groat WC (1996) Role of spinal nitric oxide in the facilitation of the micturition reflex by bladder irritation. J Urol 155(1):355–60
Zhang X, Igawa Y, Ishizuka O, Nishizawa O, Andersson K-E (2003) Effects of resiniferatoxin desensitization of capsaicin-sensitive afferents on detrusor over-activity induced by intravesical capsaicin, acetic acid or ATP in conscious rats. Naunyn Schmiedebergs Arch Pharmacol 367(5):473–9
Hino K, Honjo H, Nakao M, Kitakoji H (2010) The effects of sacral acupuncture on acetic acid-induced bladder irritation in conscious rats. Urology 75(3):730–4
Mally AD, Matsuta Y, Zhang F et al (2013) Role of opioid and metabotropic glutamate 5 receptors in pudendal inhibition of bladder overactivity in cats. J Urol 189(4):1574–9
Gratzke C, Streng T, Park A et al (2009) Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol 181(4):1939–48
Malan TP, Ibrahim MM, Deng H et al (2001) CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93(3):239–45
Castroman PJ, Ness TJ (2002) Ketamine, an N-methyl-D-aspartate receptor antagonist, inhibits the spinal neuronal responses to distension of the rat urinary bladder. Anesthesiology 96(6):1410–9
Ozkurkcugil C, Ozkan L (2010) Effects of anesthetics on cystometric parameters in female rats. Int Urol Nephrol 42(4):909–13
Gratzke C, Streng T, Stief CG et al (2010) Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol 57:1093–100
Tyagi V, Philips BJ, Su R et al (2009) Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181(4):1932–8
Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3(9):771–84
Pertwee RG, Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118(8):2053–8
Jaggar SI, Hasnie FS, Sellaturay S, Rice AS (1998) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76(1-2):189–99
Daly DM, Collins VM, Chapple CR, Grundy D (2011) The afferent system and its role in lower urinary tract dysfunction. Curr Opin Urol 21(4):268–74
Sanchez Freire V, Burkhard FC, Kessler TM, Kuhn A, Draeger A, Monastyrskaya K (2010) MicroRNAs may mediate the down-regulation of neurokinin-1 receptor in chronic bladder pain syndrome. Am J Pathol 176(1):288–303
Merriam FV, Wang ZY, Guerios SD, Bjorling DE (2008) Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci Lett 445(1):130–4
Walczak JS, Cervero F (2011) Local activation of cannabinoid CB1 receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents. Mol Pain 7:31
Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci 56(23-24):1949–55
Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997) Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61(14):PL 191-7
Acknowledgments
This study was funded by a Wellbeing of Women Training Research Fellowship awarded to Dr E Bakali.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Financial disclaimers
Professor Lambert is an administration director for Brit J. Anaesthesia.
Rights and permissions
About this article
Cite this article
Bakali, E., Mbaki, Y., Lambert, D.G. et al. Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats. Int Urogynecol J 27, 1393–1400 (2016). https://doi.org/10.1007/s00192-016-2984-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-016-2984-x